Review



pngase f solution  (New England Biolabs)


Bioz Verified Symbol New England Biolabs is a verified supplier
Bioz Manufacturer Symbol New England Biolabs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    New England Biolabs pngase f solution
    Pngase F Solution, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 8335 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pngase f solution/product/New England Biolabs
    Average 96 stars, based on 8335 article reviews
    pngase f solution - by Bioz Stars, 2026-03
    96/100 stars

    Images



    Similar Products

    96
    New England Biolabs pngase f solution
    Pngase F Solution, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pngase f solution/product/New England Biolabs
    Average 96 stars, based on 1 article reviews
    pngase f solution - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    New England Biolabs pngase f digestion solution
    Pngase F Digestion Solution, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pngase f digestion solution/product/New England Biolabs
    Average 96 stars, based on 1 article reviews
    pngase f digestion solution - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    90
    N-Zyme BioTec GmbH 0.1 μg/μl pngase f solution
    (A) Non-arthritic Cadaveric Joint (control) cadaveric tissue donors without diagnosed arthritis, osteoporosis, or fracture, and Osteoarthritis (OA) patients receiving knee replacement compose a cohort that is age, sex, and BMI matched and stratified by their clinical OARSI (arthritis) grade. Safranin-O/Fast Green histologic staining (B) of the tibial plateau of a non-arthritic donor (Control - top) and a representative patient with Osteoarthritis (OA - bottom) depict the loss of proteoglycan staining (red) in Medial OA, indicative of cartilage loss. Separation of tissue into medial and lateral sections allows for both site-matched comparisons with cadaveric tissue (medial OA vs Medial Control, blue arrow) and tissue-matched comparisons to healthier tissue from the same OA patients (OA Medial vs OA Lateral, red arrow). Formalin-fixed, paraffin-embedded (FFPE) tissue sections are prepared (C) for MALDI-MSI spatial proteomics including deparaffinization and epitope retrieval prior to <t>PNGase</t> <t>F</t> enzyme treatment for removal of proteoglycans. Tissues are matrix-coated and imaged for glycomics before being washed and prepared for peptide imaging following a similar protocol utilizing collagenase III that targets the skeletal ECM. Following matrix application, slides are imaged (D) with the timsTOF fleX mass spectrometer (Bruker).
    0.1 μg/μl Pngase F Solution, supplied by N-Zyme BioTec GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/0.1 μg/μl pngase f solution/product/N-Zyme BioTec GmbH
    Average 90 stars, based on 1 article reviews
    0.1 μg/μl pngase f solution - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Non-arthritic Cadaveric Joint (control) cadaveric tissue donors without diagnosed arthritis, osteoporosis, or fracture, and Osteoarthritis (OA) patients receiving knee replacement compose a cohort that is age, sex, and BMI matched and stratified by their clinical OARSI (arthritis) grade. Safranin-O/Fast Green histologic staining (B) of the tibial plateau of a non-arthritic donor (Control - top) and a representative patient with Osteoarthritis (OA - bottom) depict the loss of proteoglycan staining (red) in Medial OA, indicative of cartilage loss. Separation of tissue into medial and lateral sections allows for both site-matched comparisons with cadaveric tissue (medial OA vs Medial Control, blue arrow) and tissue-matched comparisons to healthier tissue from the same OA patients (OA Medial vs OA Lateral, red arrow). Formalin-fixed, paraffin-embedded (FFPE) tissue sections are prepared (C) for MALDI-MSI spatial proteomics including deparaffinization and epitope retrieval prior to PNGase F enzyme treatment for removal of proteoglycans. Tissues are matrix-coated and imaged for glycomics before being washed and prepared for peptide imaging following a similar protocol utilizing collagenase III that targets the skeletal ECM. Following matrix application, slides are imaged (D) with the timsTOF fleX mass spectrometer (Bruker).

    Journal: bioRxiv

    Article Title: Mass Spectrometry Imaging of the Subchondral Bone in Osteoarthritis Reveals Tissue Remodeling of Extracellular Matrix Proteins that Precede Cartilage Loss

    doi: 10.1101/2024.08.03.606482

    Figure Lengend Snippet: (A) Non-arthritic Cadaveric Joint (control) cadaveric tissue donors without diagnosed arthritis, osteoporosis, or fracture, and Osteoarthritis (OA) patients receiving knee replacement compose a cohort that is age, sex, and BMI matched and stratified by their clinical OARSI (arthritis) grade. Safranin-O/Fast Green histologic staining (B) of the tibial plateau of a non-arthritic donor (Control - top) and a representative patient with Osteoarthritis (OA - bottom) depict the loss of proteoglycan staining (red) in Medial OA, indicative of cartilage loss. Separation of tissue into medial and lateral sections allows for both site-matched comparisons with cadaveric tissue (medial OA vs Medial Control, blue arrow) and tissue-matched comparisons to healthier tissue from the same OA patients (OA Medial vs OA Lateral, red arrow). Formalin-fixed, paraffin-embedded (FFPE) tissue sections are prepared (C) for MALDI-MSI spatial proteomics including deparaffinization and epitope retrieval prior to PNGase F enzyme treatment for removal of proteoglycans. Tissues are matrix-coated and imaged for glycomics before being washed and prepared for peptide imaging following a similar protocol utilizing collagenase III that targets the skeletal ECM. Following matrix application, slides are imaged (D) with the timsTOF fleX mass spectrometer (Bruker).

    Article Snippet: Deglycosylation was achieved by applying a 0.1 μg/μL PNGase F solution (N-Zyme Scientifics) via the TM Sprayer M3 (HTX Imaging, Chapel Hill, NC, USA), followed by incubation in custom humid chambers for 2 hours at 37°C.

    Techniques: Control, Staining, Formalin-fixed Paraffin-Embedded, Imaging, Mass Spectrometry